AstraZeneca receives 'positive high-level results' results from Enhertu trial
7th May 2025 09:23
(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that it had received "positive high-level results" from a Phase III trial on its specifically engineered HER2-directed DXd antibody drug conjugate Enhertu.
Read moreAstraZeneca's Calquence gets Europe approval for MCL
6th May 2025 08:02
(Sharecast News) - AstraZeneca announced on Tuesday that it has secured European Commission approval for 'Calquence', or acalabrutinib, in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplant.
Read moreAstraZeneca's Breztri meets all primary endpoints in asthma trials
2nd May 2025 10:00
(Sharecast News) - AstraZeneca announced on Friday that its inhaled triple-combination therapy 'Breztri Aerosphere' met all primary endpoints in two phase three trials, delivering statistically significant and clinically meaningful improvements in lung function for patients with uncontrolled asthma.
Read moreAstraZeneca discontinues prostate cancer treatment trial
29th Apr 2025 07:10
(Sharecast News) - AstraZeneca delivered a strong performance in the first quarter of 2025, it announced on Tuesday, with total revenue rising 10% at constant exchange rates to $13.59bn, supported by double-digit growth in oncology and biopharmaceuticals across all major regions.
Read moreAstraZeneca receives positive Phase III trial results from Enhertu study
22nd Apr 2025 08:05
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it had received "positive high-level results" from a Phase III trial on its Enhertu candidate, developed in conjunction with Daiichi Sankyo.
Read moreLondon close: Stocks fall as China retaliates to latest US tariffs
9th Apr 2025 15:07
(Sharecast News) - London stocks fell sharply on Wednesday, with investors reacting to heightened geopolitical tensions after China unveiled retaliatory tariffs in response to a sweeping 104% import charge on Chinese goods announced by US president Donald Trump overnight.
Read moreAstraZeneca's Enhertu gets further EU approval
4th Apr 2025 07:02
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer, the companies said on Friday.
Read moreLondon close: Stocks slide in global reaction to Trump tariffs
3rd Apr 2025 15:29
(Sharecast News) - London stocks closed sharply lower on Thursday as global markets reacted negatively to US president Donald Trump's unexpectedly aggressive global tariff policy announced overnight.
Read moreUK pharma stocks avoid selloff
3rd Apr 2025 10:18
(Sharecast News) - GSK and AstraZeneca avoided the selloff on Thursday as pharmaceutical products were exempt from Donald's Trump's tariffs.
Read moreAstraZeneca makes regulatory progress with Imfinzi, Calquence
31st Mar 2025 07:21
(Sharecast News) - AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its oncology therapies, Imfinzi and Calquence, marking progress in its immunotherapy and haematology pipelines.
Read moreAstraZeneca spending $2.5bn on new R&D centre, biotech deals in China
21st Mar 2025 11:17
(Sharecast News) - Pharma giant AstraZeneca announced on Friday that it is investing $2.5bn in a new global R&D centre in China, along with major research and manufacturing agreements with three of the country's biotech firms.
Read moreAstraZeneca buys biotech firm Esobiotec for up to $1bn
17th Mar 2025 07:21
(Sharecast News) - AstraZeneca announced on Monday that it is spending up to $1bn to acquire Belgian biotech firm EsoBiotec, which it says has the potential to "transform" cell therapy.
Read moreAstraZeneca hails trial results for imfinzi on gastric cancer
7th Mar 2025 07:03
(Sharecast News) - AstraZeneca said its Imfinzi drug when used with chemotherapy had shown "statistically significant and clinically meaningful improvement" in survival in resectable early-stage gastric and gastroesophageal cancers before surgery.
Read moreAstraZeneca's Imfinzi gets recommended for fresh EU approval
3rd Mar 2025 07:26
(Sharecast News) - AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and without EGFR mutations or ALK rearrangements.
Read moreAstraZeneca's camizestrant shows promise in breast cancer trial
26th Feb 2025 08:07
(Sharecast News) - AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in the first-line treatment of hormone receptor-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
Read more